Journal article icon

Journal article

An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.

Abstract:

BACKGROUND: Although combining targeted agents with conventional, first-line cytotoxic therapy has improved survival outcomes in patients with advanced colorectal cancer, further improvements in outcomes and tolerability are needed. METHODS: This phase I study evaluated the feasibility of combining oral pazopanib, an agent that targets multiple proangiogenic factors, with FOLFOX6 (oxaliplatin, leucovorin, and 5-fluorouracil) or CapeOx (oxaliplatin and capecitabine). This phase I study evaluat...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s10637-013-9938-7

Authors


Journal:
Investigational new drugs More from this journal
Volume:
31
Issue:
5
Pages:
1228-1235
Publication date:
2013-10-01
DOI:
EISSN:
1573-0646
ISSN:
0167-6997
Language:
English
Keywords:
Pubs id:
pubs:387827
UUID:
uuid:cdefa5e7-1712-4305-8b1c-1d7fb07b71b8
Local pid:
pubs:387827
Source identifiers:
387827
Deposit date:
2013-11-16

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP